Gemita RTU 38mg/ml Injection

Manufacturer
Fresenius Kabi Oncology Limited(INDIA)

Registraction Number
MAL20016143AZ

Content:
Gemita RTU 38mg/ml Injection contains the active ingredient gemcitabine hydrochloride. Each mL of the solution contains 38 mg of gemcitabine hydrochloride.
Indications:
Gemita RTU is used for the treatment of:
Non-Small Cell Lung Cancer (NSCLC): As a single agent or in combination with cisplatin.
Pancreatic Cancer: As a single agent.
Breast Cancer: In combination with paclitaxel.
Bladder Cancer: In combination with cisplatin.
Instructions:
Dosage:
NSCLC: The recommended dose is 1,000 mg/m², given by 30-minute intravenous infusion once weekly for three weeks, followed by a one-week rest period. This four-week cycle is then repeated.
Pancreatic Cancer: The recommended dose is 1,000 mg/m², given by 30-minute intravenous infusion once weekly for up to seven weeks, followed by a week of rest. Subsequent cycles consist of injections once weekly for three consecutive weeks out of every four weeks.
Breast Cancer: In combination with paclitaxel, the recommended dose is 1,250 mg/m², given by 30-minute intravenous infusion on days 1 and 8 of each 21-day cycle.
Bladder Cancer: In combination with cisplatin, the recommended dose is 1,000 mg/m², given by 30-minute intravenous infusion on days 1, 8, and 15 of each 28-day cycle.
Administration:
Administer the injection intravenously (IV) by bolus injection or continuous infusion.
Ensure the immediate availability of oxygen and other resuscitative equipment when administering the injection.
Missed Dose: This medication is typically administered by a healthcare professional in a clinical setting, so missed doses are not common.